Table 1.
Clinical information of patients with ALS and HCs.
| ALS | HCs | |
|---|---|---|
| n = 30 | n = 20 | |
| Male, n (%) | 21 (70.0) | 5 (25.0) |
| Age* | 59.0 (52.5–64.0) | 26.0 (24.0–45.8) |
| Disease duration (months)* | 17.8 (12.4–29.1) | NA |
| Diagnostic delay (months)* (n = 25) | 8.0 (4.9–12.0) | NA |
| Site of onset | NA | |
| Spinal onset, n (%) | 22 (73.3) | |
| Bulbar onset, n (%) | 8 (26.7) | |
| ALSFRS-r* (n = 26) | 33.0 (29.3–42.0) | NA |
| DPR* (n = 26) | 0.49 (0.25–0.83) | NA |
| FVC* (n = 18) | 74.1 (70.0–79.0) | NA |
| Clinical stage, n (%) | NA | |
| Stage 2 | 10 (33.3) | |
| Stage 3 | 11 (36.7) | |
| Stage 4 | 9 (30) | |
| Riluzole, n (%) | 20 (66.7) | NA |
ALS, amyotrophic lateral sclerosis; ALSFRS-r, amyotrophic lateral sclerosis functional rating scale revised; DPR, Disease progression rate; FVC, forced vital capacity; HCs, Healthy controls; NA, not available; NFL, Neurofilament light chain.
*
Data are presented as median (interquartile range).